Anthem Biosciences LimitedANTHEMCorporate

Healthcare Biotechnology Latest results: Jun 2026 6 quarters of data

₹822.15

MCap ₹46,181 Cr · P/E 73.9

Anthem Biosciences Limited — Stock analysis & AI research Anthem Biosciences Limited — Seasonality — best & worst months Anthem Biosciences Limited — Technical indicators & charts Anthem Biosciences Limited — Technical setup — score, trend, support & resistance Anthem Biosciences Limited — Live exchange announcements

📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 High Promoter Holding Stocks 📋 Mid Cap Stocks List 📈 20-Day Breakdown Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹384 Cr

Sales · Jun 2026

-28.7% YoY

₹131 Cr

Operating Profit · Jun 2026

-33.1% YoY

34.1%

OPM % · Jun 2026

-6.1% YoY

₹102 Cr

Net Profit · Jun 2026

-31.2% YoY

₹1.81

EPS · Jun 2026

-31.7% YoY

📝 Anthem Biosciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Anthem Biosciences Limited reported revenue of ₹384 crore for the quarter ended June 2026 (Q1 FY27), down 28.7% from ₹538 crore in the same quarter last year, and down 34.0% sequentially over the March 2026 quarter.

Net profit fell 31.2% year-on-year to ₹102 crore, from ₹148 crore. Earnings per share (EPS) came in at ₹1.81.

Operating profit stood at ₹131 crore — an operating margin (OPM) of 34.1%, compared with 36.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Anthem Biosciences Limited posted revenue of ₹2,089 crore, with a net profit of ₹671 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,935 crore with a net profit of ₹625 crore.

Valuation snapshot

At the current price of ₹822.15, ANTHEM has a market capitalisation of ₹46,181 crore and a trailing P/E of about 73.9.

Within the Biotechnology industry, it is the 2nd-largest of the 8 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 71.40%, foreign institutional investors (FIIs) 3.79%, domestic institutional investors (DIIs) 12.10%, public shareholders 12.70% of Anthem Biosciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹46,181 Cr

Current Price ?

₹822.1

P/E ?

73.94below ind

Industry P/E ?

106.70

P/B ?

N/A

P/S ?

23.87

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.4%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹1,935 Cr

OPM ?

40.7%

Profit after tax (TTM) ?

₹625 Cr

EPS (TTM) ?

₹11.12

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹384 Cr

PAT — latest qtr ?

₹102 Cr

YoY qtr sales growth ?

-28.7%

YoY qtr profit growth ?

-31.2%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

107.9

Current Ratio ?

N/A

Ownership

Promoter holding ?

71.40%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

5.8%

Return 6 months ?

14.0%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	479	538	552	417	582	384	-28.7%	-34.0%
Operating Profit	198	195	226	163	267	131	-33.1%	-51.0%
Other Income	38	28	54	40	62	29	+3.1%	-53.9%
Interest	2	2	2	1	2	1	-52.5%	-61.9%
Depreciation	21	23	24	27	26	22	-1.3%	-14.2%
Profit Before Tax	213	199	253	150	301	136	-31.5%	-54.7%
Net Profit	123	148	198	112	212	102	-31.2%	-51.9%
EPS	2.19	2.65	3.54	2.00	3.77	1.81	-31.7%	-52.0%
OPM %	41.3%	36.3%	40.9%	39.1%	45.9%	34.1%	-6.1%	-25.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹2,089 Cr	₹1,935 Cr	—
Operating Profit	—	₹851 Cr	₹787 Cr	—
OPM %	—	40.75%	40.66%	—
NPM %	—	32.12%	32.28%	—
Other Income	—	₹183 Cr	₹184 Cr	—
Depreciation	—	₹99 Cr	₹99 Cr	—
Interest	—	₹7 Cr	₹6 Cr	—
EBIT	—	₹752 Cr	₹688 Cr	—
PBT	—	₹903 Cr	₹841 Cr	—
Tax	—	₹143 Cr	₹127 Cr	—
Net Profit	—	₹671 Cr	₹625 Cr	—
EPS	—	₹11.96	₹11.12	—
Material Cost	—	₹547 Cr	₹529 Cr	—
Employee Cost	—	₹197 Cr	₹201 Cr	—
Extraordinary Items	—	₹25 Cr	₹25 Cr	—

👥 Shareholding (latest 1 periods)

Metric	Sep 2026	% Chg
Promoters	71.40%	—
FIIs	3.79%	—
DIIs	12.10%	—
Public	12.70%	—
No. of Shareholders	1,76,209	—

⚖️ Peer comparison

Industry: Biotechnology · 8 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	BIOCON Biocon	₹390.65	63,609	147.4	17,322	417	20.4%	2.4%	10.9%	-74.2%	10.0%	53.4%
2	ANTHEM ANTHEM BIOSCIENCES	₹874.85	49,142	85.4	2,002	576	39.6%	28.8%	—	—	-22.6%	-11.7%
3	ONESOURCE ONESOURCE SPECL	₹1,592.00	18,256	—	1,544	-49	21.9%	-3.2%	-1.6%	-185.0%	37.3%	0.7%
4	CONCORDBIO Concord Biotech	₹1,510.00	15,797	57.6	1,109	273	34.9%	24.6%	-12.1%	-30.4%	26.2%	31.0%
5	514336 CCME Global	₹15.10	150	—	0	-1	-2079.0%	-2135.5%	-98.9%	-120.3%	—	-120.2%
6	511509 Vivo Bio	₹37.69	37	—	55	-3	37.0%	-5.2%	14.3%	-123.4%	14.1%	-86.0%
7	539470 Shree Ganesh	₹1.20	18	—	5	-0	-35.3%	-7.8%	-78.4%	34.2%	3.6%	-273.7%
8	539206 Genomic Valley	₹52.00	9	n/m	0	0	11.7%	6.7%	-68.2%	-94.4%	-57.8%	-26.9%

❓ Frequently asked questions

What was Anthem Biosciences Limited's revenue in Q1 FY27?

What was Anthem Biosciences Limited's net profit in Q1 FY27?